This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 27 PubMed articles · model: gemma4:31b
Summary
Kratom (Mitragyna speciosa) is a tropical plant from Southeast Asia with psychoactive properties that produce analgesic, stimulant, and opioid-like effects [PMID:31643556, PMID:36256767].
Background
Kratom is an herbal product derived from the leaves of Mitragyna speciosa, a tropical evergreen tree native to Southeast Asia [PMID:31643556, PMID:36256767]. It is consumed globally as a tea, powder, or in capsules [PMID:36256767, PMID:28484399].
Traditional uses
Traditionally used in Southeast Asia and parts of Africa to increase the stamina of outdoor laborers, manage pain, treat diarrhea, and stave off fatigue [PMID:36256767, PMID:28484399, PMID:37364801].
Active compounds
Kratom contains over 40 alkaloids [PMID:34775626, PMID:39640144]. The primary psychoactive compounds are mitragynine and 7-hydroxymitragynine [PMID:31643556, PMID:34775626]. Other identified compounds include corynantheidine and speciogynine [PMID:31643556, PMID:37518950].
Mechanism of action
Alkaloids in kratom interact with opioid (mu, delta, and kappa), adrenergic, serotonergic, and dopaminergic receptors [PMID:38217374, PMID:34775626, PMID:36594896]. Mitragynine and 7-hydroxymitragynine act as partial mu- and kappa-opioid agonists [PMID:31643556].
Clinical evidence
Evidence BPain Management
Preclinical evidence and one randomized controlled trial support its therapeutic value as an analgesic [PMID:37266188].
Evidence COpioid Use Disorder/Withdrawal
Used as an alternative for treating opioid withdrawal symptoms and managing cravings [PMID:31999896, PMID:37266188].
Evidence DSleep
Bedtime use was associated with modest increases in self-reported sleep duration and quality in a 15-day study of adults [PMID:40839514].
Evidence CCognition
Mitragynine may adversely affect cognitive performances by disrupting synaptic plasticity and brain activity [PMID:39643045].
Safety & adverse effects
Adverse effects include potential for dependence, withdrawal, and life-threatening toxicity [PMID:31999896]. Specific risks include acute liver injury and hepatotoxicity characterized by cholestatic patterns and perivenular necrosis [PMID:31643556, PMID:35399621, PMID:31919755]. Other reported effects include cardiotoxicity, seizures, psychosis, and cardiovascular, gastrointestinal, and psychiatric issues [PMID:34646135, PMID:28484399, PMID:35645563].
Pregnancy & lactation
In-utero exposure has raised concerns regarding the risk of neonatal abstinence syndrome [PMID:35645563]. Scientific evidence specific to therapeutic and adverse effects in pregnancy is limited to a few case reports [PMID:37679866].
Drug interactions
Kratom's bioactive alkaloids can significantly impact the pharmacokinetics and pharmacodynamics of concomitant medications, though specific human drug interaction studies are limited [PMID:40522665, PMID:29255059].
Dosage & administration
Some individuals using kratom for chronic pain, depression, and anxiety typically consume 1-3 grams daily in powder form [PMID:39640144]. No PubMed data available. Consult a healthcare provider.
Evidence summary
The evidence is primarily based on reviews, case reports, and preclinical data (Levels C and D), with very limited high-level clinical trial data (Level B).
PubMed sources
1.PMID: 31999896 (2020) — Kratom (Mitragyna speciosa): Friend or Foe? · The primary care companion for CNS disorders
2.PMID: 38217374 (2024) — An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. · Expert review of clinical pharmacology
3.PMID: 31643556 (2012) — The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. · International journal of legal medicine
4.PMID: 36256767 (2026) — Kratom (Mitragyna speciosa): worldwide issues. · Current opinion in psychiatry
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
6.PMID: 37983284 (2023) — Pharmacology and toxicology of kratom. · Bratislavske lekarske listy
7.PMID: 36594896 (2023) — Kratom Alkaloids: A Blueprint? · ACS chemical neuroscience
8.PMID: 37518950 (2023) — Biosynthesis of kratom opioids. · The New phytologist
9.PMID: 34775626 (2022) — Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa). · Journal of clinical pharmacology
10.PMID: 35645563 (2022) — Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review. · Substance abuse : research and treatment
11.PMID: 36883326 (2023) — Directed Biosynthesis of Mitragynine Stereoisomers. · Journal of the American Chemical Society
12.PMID: 28947930 (2017) — Mitragyna speciosa: Balancing Potential Medical Benefits and Abuse. · ACS medicinal chemistry letters
13.PMID: 28484399 (2017) — Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom. · Frontiers in psychiatry
14.PMID: 37266188 (2023) — Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review. · Current addiction reports
15.PMID: 35767669 (2022) — Kratom use as more than a "self-treatment". · The American journal of drug and alcohol abuse
17.PMID: 29255059 (2018) — Pharmacologic and clinical assessment of kratom. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
18.PMID: 37679866 (2024) — Kratom (Mitragyna speciosa): A Case Review of Use Before and During Pregnancy. · Journal of midwifery & women's health
19.PMID: 40839514 (2025) — Is bedtime use of kratom (Mitragyna speciosa) a sleep aid or disruptor? Examining its daily effects and individual differences. · Experimental and clinical psychopharmacology
20.PMID: 39643045 (2025) — Exploring the cognitive effects of kratom: A review. · Behavioural brain research
21.PMID: 34646135 (2021) — The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review. · Frontiers in pharmacology
22.PMID: 40522665 (2025) — Evaluating the drug interactions in kratom usage: clinical application. · Expert opinion on drug metabolism & toxicology
23.PMID: 39640144 (2024) — Kratom: A Narrative Review of the Possible Clinical Uses and Dangers of This Opioid-Like Plant. · Cureus
24.PMID: 32153252 (2020) — Public Perceptions toward Kratom (Mitragyna Speciosa) Use in Malaysia. · Journal of psychoactive drugs
25.PMID: 37364801 (2023) — Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects. · Journal of ethnopharmacology
26.PMID: 36798621 (2023) — Investigating the Impact of Kratom (Mitragyna speciosa) Use Upon Male Sexual Health. · Research and reports in urology